CSF1R Specific Neutra™ Antibody Products

Are you struggling with extended drug development timelines or challenges in modulating macrophage-associated signaling networks? Creative Biolabs' CSF1R specific Neutra™ antibody products leverage advanced monoclonal engineering and high-throughput validation platforms to enable rapid, reproducible targeting of Colony Stimulating Factor 1 Receptor (CSF1R), accelerating therapeutic discovery for oncology, fibrosis, and inflammatory diseases.

Introduction to CSF1R

Colony Stimulating Factor 1 Receptor (CSF1R), encoded by the CSF1R gene, is a tyrosine kinase receptor critical for the survival, differentiation, and functional polarization of macrophages and osteoclasts. It binds two primary ligands—CSF1 and interleukin-34 (IL-34)—to orchestrate myeloid cell dynamics across tissues. Dysregulated CSF1R signaling is implicated in tumor microenvironments, chronic inflammation, and bone remodeling disorders, making it a pivotal therapeutic target.

• Structure

The CSF1R protein comprises an extracellular ligand-binding domain with five immunoglobulin-like folds, a transmembrane helix, and an intracellular tyrosine kinase domain. Ligand binding induces receptor dimerization, triggering autophosphorylation of tyrosine residues within the kinase domain. This activates downstream cascades, including PI3K/AKT, MAPK/ERK, and JAK/STAT pathways. Structural studies reveal distinct conformational changes in CSF1R's extracellular domain upon CSF1 versus IL-34 binding, which influence signaling potency and cellular outcomes.

• Related Signaling Pathways

CSF1R activation stimulates two canonical pathways:
- CSF1/CSF1R Axis: Predominantly regulates tissue-resident macrophage proliferation and tumor-associated macrophage (TAM) recruitment in cancers.
- IL-34/CSF1R Axis: Mediates microglial maintenance in the central nervous system and osteoclastogenesis in bone.
Both pathways intersect with immunosuppressive networks (e.g., PD-1/PD-L1) and pro-fibrotic signaling (e.g., TGF-β), amplifying disease progression in malignancies and fibrotic disorders.

Fig.1 Signaling pathways of CSF1R-mediated microglial survival and proliferation.¹

• Pathologies

CSF1R hyperactivity drives tumor immune evasion in glioblastoma, breast cancer, and tenosynovial giant cell tumors (TGCT). Conversely, aberrant CSF1R suppression correlates with osteoporosis, Alzheimer's disease, and rheumatoid arthritis. In chronic inflammation, CSF1R sustains pathogenic macrophage populations that exacerbate organ fibrosis and autoimmune responses.

Applications of CSF1R Neutralizing Antibodies

• Oncology: Depleting Tumor-Promoting Macrophages

CSF1R blockade reduces TAM infiltration in solid tumors, reversing immunosuppression and enhancing T-cell-mediated cytotoxicity. Clinically, anti-CSF1R antibodies synergize with checkpoint inhibitors to improve objective response rates in melanoma and pancreatic cancer models.

• Chronic Inflammatory Disorders: Restoring Immune Homeostasis

In rheumatoid arthritis and systemic sclerosis, neutralizing CSF1R limits the expansion of pro-inflammatory M1 macrophages, attenuating tissue damage and fibrosis. Preclinical studies show reduced synovial hyperplasia and collagen deposition in treated cohorts.

• Bone-Related Diseases: Targeting Osteoclastogenesis

Anti-CSF1R antibodies inhibit osteoclast formation in osteoporosis and bone metastasis, preserving bone density and mitigating skeletal-related events.

• Diagnostic Development: Biomarker Quantification

CSF1R expression levels in serum or biopsy samples serve as prognostic indicators for disease severity and treatment response. Our antibodies enable precise CSF1R detection in ELISA and multiplex immunoassays.

Our Anti-CSF1R Antibodies

Creative Biolabs' CSF1R specific antibodies are engineered to disrupt ligand-receptor binding with sub-nanomolar affinity, effectively blocking downstream pro-tumorigenic and inflammatory signaling. These antibodies exhibit:
- Cross-reactivity: Validated for human, mouse, and primate CSF1R.
- Functional specificity: Neutralize both CSF1- and IL-34-mediated activation without off-target effects on related tyrosine kinase receptors (e.g., KIT, FLT3).
- Application versatility: Optimized for in vivo pharmacokinetics and compatibility with immunotherapy combinations.
Creative Biolabs delivers rigorously validated CSF1R specific Neutra™ antibodies, backed by orthogonal binding and functional assays, to empower transformative discoveries in immunotherapy and beyond. Contact our team today to discuss customized solutions for your project.

REFERENCE

1. Hu, Banglian, et al. "Insights into the role of CSF1R in the central nervous system and neurological disorders." Frontiers in aging neuroscience 13 (2021): 789834. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fnagi.2021.789834